Susan Gregory
Pulmonary Disease · Wynnewood, PANPI 1619913308
Payments from drug & device makers
Across 117 payments — averaging $43.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$3K
- GSK$403
- Mylan Specialty L.p.$236
- Boehringer Ingelheim$208
- Genentech USA, Inc.$97
- Insmed, Inc.$93
- plus $611 from 15 others
What the payments were for
- Consulting fees$2,72354%
- Food & beverage$2,31246%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 37 | $3,387 |
| GSK | 22 | $403 |
| Mylan Specialty L.p. | 12 | $236 |
| Boehringer Ingelheim | 9 | $208 |
| Genentech USA, Inc. | 5 | $97 |
| Insmed, Inc. | 3 | $93 |
| Sanofi | 4 | $81 |
| Actelion Pharmaceuticals US, Inc. | 3 | $67 |
| Mallinckrodt Enterprises LLC | 2 | $51 |
| Gilead | 2 | $51 |
| Regeneron Healthcare Solutions, Inc. | 2 | $49 |
| Grifols USA, LLC | 2 | $48 |
| Circassia Inc. | 3 | $46 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $41 |
| Amgen | 2 | $37 |
| Philips North America LLC | 2 | $33 |
| Jazz Pharmaceuticals Inc. | 1 | $31 |
| United Therapeutics Corporation | 1 | $24 |
| AbbVie | 1 | $19 |
| Teva Pharmaceuticals USA, Inc. | 1 | $18 |
| Bristol Myers Squibb | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- IMFINZI$2,723
How this compares
$5,035 in reported general payments places this provider in the 65th percentile of 703 pulmonary disease providers in Pennsylvania.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 24 | $17,880 |
| Breo ElliptaFluticasone/Vilanterol | 11 | $4,583 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 11 | $239 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta | $403 | $22,46335 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 703 pulmonary disease providers in Pennsylvania.
Other pulmonary disease in Wynnewood
- Thomas MeyerWynnewood$615K
- Eliot FriedmanWynnewood$254K
- Jacqueline SutterWynnewood$216K
- Gerard CrinerPhiladelphia$18.2M
- Sandeep Bansaldu Bois$8.9M
- David WheelerPhiladelphia$7.7M
- Steven AlbeldaPhiladelphia$5.5M
- Paul SimonelliDanville$2.1M
- Kevin GibsonPittsburgh$1.3M
- Frank SciurbaPittsburgh$1.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.